25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AUROBINDO PHARMA LTD.
Buy, Hold or Sell?

Let's analyze Aurobindo together

I guess you are interested in AUROBINDO PHARMA LTD.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of AUROBINDO PHARMA LTD.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about AUROBINDO PHARMA LTD.

I send you an email if I find something interesting about AUROBINDO PHARMA LTD..

1. Quick Overview

1.1. Quick analysis of Aurobindo (30 sec.)










1.2. What can you expect buying and holding a share of Aurobindo? (30 sec.)

How much money do you get?

How much money do you get?
INR0.21
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR509.45
Expected worth in 1 year
INR714.18
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
INR222.73
Return On Investment
17.6%

For what price can you sell your share?

Current Price per Share
INR1,262.40
Expected price per share
INR1,109 - INR1,582
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aurobindo (5 min.)




Live pricePrice per Share (EOD)
INR1,262.40
Intrinsic Value Per Share
INR-507.31 - INR-21.98
Total Value Per Share
INR2.15 - INR487.47

2.2. Growth of Aurobindo (5 min.)




Is Aurobindo growing?

Current yearPrevious yearGrowGrow %
How rich?$3.5b$3.1b$353.8m10.0%

How much money is Aurobindo making?

Current yearPrevious yearGrowGrow %
Making money$374.4m$227.4m$146.9m39.3%
Net Profit Margin11.1%7.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Aurobindo (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aurobindo?

Welcome investor! Aurobindo's management wants to use your money to grow the business. In return you get a share of Aurobindo.

First you should know what it really means to hold a share of Aurobindo. And how you can make/lose money.

Speculation

The Price per Share of Aurobindo is INR1,262. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aurobindo.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aurobindo, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR509.45. Based on the TTM, the Book Value Change Per Share is INR51.18 per quarter. Based on the YOY, the Book Value Change Per Share is INR38.87 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR4.50 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aurobindo.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.640.1%0.640.1%0.390.0%0.640.1%0.610.0%
Usd Book Value Change Per Share0.600.0%0.600.0%0.460.0%0.640.1%1.000.1%
Usd Dividend Per Share0.050.0%0.050.0%0.090.0%0.060.0%0.050.0%
Usd Total Gains Per Share0.660.1%0.660.1%0.550.0%0.700.1%1.050.1%
Usd Price Per Share12.86-12.86-6.11-8.43-8.57-
Price to Earnings Ratio20.12-20.12-15.75-13.77-14.72-
Price-to-Total Gains Ratio19.57-19.57-11.17-12.34-10.83-
Price to Book Ratio2.14-2.14-1.13-1.73-2.00-
Price-to-Total Gains Ratio19.57-19.57-11.17-12.34-10.83-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share14.89632
Number of shares67
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.050.06
Usd Book Value Change Per Share0.600.64
Usd Total Gains Per Share0.660.70
Gains per Quarter (67 shares)44.0246.78
Gains per Year (67 shares)176.09187.12
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11416216615172177
22832434230345364
34348651845517551
45764769459689738
57180987074861925
68597110468910341112
71001133122210412061299
81141295139811913781486
91281457157413415501673
101421619175014917231860

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%6.00.00.0100.0%6.00.00.0100.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of AUROBINDO PHARMA LTD. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--51.18251.1820%38.874+32%54.469-6%84.909-40%
Book Value Per Share--509.453509.4530%458.271+11%409.655+24%380.896+34%
Current Ratio--1.9841.9840%1.875+6%1.876+6%1.776+12%
Debt To Asset Ratio--0.3380.3380%0.327+3%0.342-1%0.364-7%
Debt To Equity Ratio--0.5100.5100%0.486+5%0.528-3%0.591-14%
Dividend Per Share--4.4994.4990%7.501-40%4.699-4%4.332+4%
Eps--54.15254.1520%32.896+65%54.3690%52.034+4%
Free Cash Flow Per Share---19.234-19.2340%-5.694-70%17.942-207%14.999-228%
Free Cash Flow To Equity Per Share---19.234-19.2340%25.272-176%2.695-814%7.752-348%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---21.978--------
Intrinsic Value_10Y_min---507.307--------
Intrinsic Value_1Y_max--13.630--------
Intrinsic Value_1Y_min---9.289--------
Intrinsic Value_3Y_max--28.886--------
Intrinsic Value_3Y_min---64.061--------
Intrinsic Value_5Y_max--29.596--------
Intrinsic Value_5Y_min---158.030--------
Market Cap733204424601.600+13%638350817575.050638350817575.0500%303516199462.000+110%418477354547.800+53%425486073568.833+50%
Net Profit Margin--0.1110.1110%0.078+41%0.129-14%0.128-14%
Operating Margin----0%0.102-100%0.120-100%0.128-100%
Operating Ratio--1.3081.3080%1.357-4%1.287+2%1.286+2%
Pb Ratio2.478+14%2.1382.1380%1.130+89%1.732+23%1.996+7%
Pe Ratio23.312+14%20.11820.1180%15.747+28%13.771+46%14.722+37%
Price Per Share1262.400+14%1089.4501089.4500%518.000+110%714.200+53%726.167+50%
Price To Free Cash Flow Ratio-65.635-16%-56.643-56.6430%-90.968+61%-17.391-69%447.330-113%
Price To Total Gains Ratio22.672+14%19.56619.5660%11.170+75%12.337+59%10.828+81%
Quick Ratio--0.6350.6350%0.574+11%0.497+28%0.490+30%
Return On Assets--0.0700.0700%0.048+46%0.090-22%0.090-22%
Return On Equity--0.1060.1060%0.072+48%0.140-24%0.145-26%
Total Gains Per Share--55.68155.6810%46.376+20%59.169-6%89.240-38%
Usd Book Value--3522394400.0003522394400.0000%3168518300.000+11%2832382556.000+24%2633535406.667+34%
Usd Book Value Change Per Share--0.6040.6040%0.459+32%0.643-6%1.002-40%
Usd Book Value Per Share--6.0126.0120%5.408+11%4.834+24%4.495+34%
Usd Dividend Per Share--0.0530.0530%0.089-40%0.055-4%0.051+4%
Usd Eps--0.6390.6390%0.388+65%0.6420%0.614+4%
Usd Free Cash Flow---132983640.000-132983640.0000%-39370700.000-70%124053636.000-207%103704890.000-228%
Usd Free Cash Flow Per Share---0.227-0.2270%-0.067-70%0.212-207%0.177-228%
Usd Free Cash Flow To Equity Per Share---0.227-0.2270%0.298-176%0.032-814%0.091-348%
Usd Market Cap8651812210.299+13%7532539647.3867532539647.3860%3581491153.652+110%4938032783.664+53%5020735668.112+50%
Usd Price Per Share14.896+14%12.85612.8560%6.112+110%8.428+53%8.569+50%
Usd Profit--374410460.000374410460.0000%227445000.000+65%375580548.0000%359490146.667+4%
Usd Revenue--3387131000.0003387131000.0000%2904821340.000+17%2926024288.000+16%2816463530.000+20%
Usd Total Gains Per Share--0.6570.6570%0.547+20%0.698-6%1.053-38%
 EOD+5 -3MRQTTM+0 -0YOY+21 -145Y+13 -2210Y+18 -17

3.3 Fundamental Score

Let's check the fundamental score of AUROBINDO PHARMA LTD. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1523.312
Price to Book Ratio (EOD)Between0-12.478
Net Profit Margin (MRQ)Greater than00.111
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.635
Current Ratio (MRQ)Greater than11.984
Debt to Asset Ratio (MRQ)Less than10.338
Debt to Equity Ratio (MRQ)Less than10.510
Return on Equity (MRQ)Greater than0.150.106
Return on Assets (MRQ)Greater than0.050.070
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of AUROBINDO PHARMA LTD. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.914
Ma 20Greater thanMa 501,284.960
Ma 50Greater thanMa 1001,395.216
Ma 100Greater thanMa 2001,430.935
OpenGreater thanClose1,239.000
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About AUROBINDO PHARMA LTD.

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Fundamental data was last updated by Penke on 2024-11-17 04:00:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aurobindo earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 11.1% means that ₹0.11 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AUROBINDO PHARMA LTD.:

  • The MRQ is 11.1%. The company is making a huge profit. +2
  • The TTM is 11.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ11.1%TTM11.1%0.0%
TTM11.1%YOY7.8%+3.2%
TTM11.1%5Y12.9%-1.8%
5Y12.9%10Y12.8%+0.1%
4.3.1.2. Return on Assets

Shows how efficient Aurobindo is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • 7.0% Return on Assets means that Aurobindo generated ₹0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AUROBINDO PHARMA LTD.:

  • The MRQ is 7.0%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 7.0%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ7.0%TTM7.0%0.0%
TTM7.0%YOY4.8%+2.2%
TTM7.0%5Y9.0%-2.0%
5Y9.0%10Y9.0%+0.0%
4.3.1.3. Return on Equity

Shows how efficient Aurobindo is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • 10.6% Return on Equity means Aurobindo generated ₹0.11 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AUROBINDO PHARMA LTD.:

  • The MRQ is 10.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 10.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ10.6%TTM10.6%0.0%
TTM10.6%YOY7.2%+3.5%
TTM10.6%5Y14.0%-3.3%
5Y14.0%10Y14.5%-0.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of AUROBINDO PHARMA LTD..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aurobindo is operating .

  • Measures how much profit Aurobindo makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AUROBINDO PHARMA LTD.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY10.2%-10.2%
TTM-5Y12.0%-12.0%
5Y12.0%10Y12.8%-0.9%
4.3.2.2. Operating Ratio

Measures how efficient Aurobindo is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.31 means that the operating costs are ₹1.31 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of AUROBINDO PHARMA LTD.:

  • The MRQ is 1.308. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.308. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.308TTM1.3080.000
TTM1.308YOY1.357-0.048
TTM1.3085Y1.287+0.021
5Y1.28710Y1.286+0.001
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of AUROBINDO PHARMA LTD..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aurobindo is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.98 means the company has ₹1.98 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of AUROBINDO PHARMA LTD.:

  • The MRQ is 1.984. The company is able to pay all its short-term debts. +1
  • The TTM is 1.984. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.984TTM1.9840.000
TTM1.984YOY1.875+0.110
TTM1.9845Y1.876+0.108
5Y1.87610Y1.776+0.100
4.4.3.2. Quick Ratio

Measures if Aurobindo is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.64 means the company can pay off ₹0.64 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AUROBINDO PHARMA LTD.:

  • The MRQ is 0.635. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.635. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.635TTM0.6350.000
TTM0.635YOY0.574+0.061
TTM0.6355Y0.497+0.138
5Y0.49710Y0.490+0.008
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of AUROBINDO PHARMA LTD..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aurobindo assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aurobindo to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.34 means that Aurobindo assets are financed with 33.8% credit (debt) and the remaining percentage (100% - 33.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AUROBINDO PHARMA LTD.:

  • The MRQ is 0.338. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.338. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.338TTM0.3380.000
TTM0.338YOY0.327+0.011
TTM0.3385Y0.342-0.005
5Y0.34210Y0.364-0.022
4.5.4.2. Debt to Equity Ratio

Measures if Aurobindo is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 51.0% means that company has ₹0.51 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AUROBINDO PHARMA LTD.:

  • The MRQ is 0.510. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.510. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.510TTM0.5100.000
TTM0.510YOY0.486+0.024
TTM0.5105Y0.528-0.018
5Y0.52810Y0.591-0.063
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Aurobindo generates.

  • Above 15 is considered overpriced but always compare Aurobindo to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 20.12 means the investor is paying ₹20.12 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AUROBINDO PHARMA LTD.:

  • The EOD is 23.312. Based on the earnings, the company is fair priced.
  • The MRQ is 20.118. Based on the earnings, the company is fair priced.
  • The TTM is 20.118. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD23.312MRQ20.118+3.194
MRQ20.118TTM20.1180.000
TTM20.118YOY15.747+4.372
TTM20.1185Y13.771+6.347
5Y13.77110Y14.722-0.951
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AUROBINDO PHARMA LTD.:

  • The EOD is -65.635. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -56.643. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -56.643. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-65.635MRQ-56.643-8.992
MRQ-56.643TTM-56.6430.000
TTM-56.643YOY-90.968+34.326
TTM-56.6435Y-17.391-39.252
5Y-17.39110Y447.330-464.721
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aurobindo is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.14 means the investor is paying ₹2.14 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of AUROBINDO PHARMA LTD.:

  • The EOD is 2.478. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.138. Based on the equity, the company is underpriced. +1
  • The TTM is 2.138. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.478MRQ2.138+0.339
MRQ2.138TTM2.1380.000
TTM2.138YOY1.130+1.008
TTM2.1385Y1.732+0.407
5Y1.73210Y1.996-0.264
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets450,715,100
Total Liabilities152,207,100
Total Stockholder Equity298,428,000
 As reported
Total Liabilities 152,207,100
Total Stockholder Equity+ 298,428,000
Total Assets = 450,715,100

Assets

Total Assets450,715,100
Total Current Assets242,056,300
Long-term Assets208,658,800
Total Current Assets
Cash And Cash Equivalents 33,934,800
Short-term Investments 29,316,900
Net Receivables 48,167,400
Inventory 98,082,300
Other Current Assets 25,364,300
Total Current Assets  (as reported)242,056,300
Total Current Assets  (calculated)234,865,700
+/- 7,190,600
Long-term Assets
Property Plant Equipment 144,116,900
Goodwill 5,951,500
Intangible Assets 34,814,600
Long-term Assets Other 2,299,600
Long-term Assets  (as reported)208,658,800
Long-term Assets  (calculated)187,182,600
+/- 21,476,200

Liabilities & Shareholders' Equity

Total Current Liabilities121,991,300
Long-term Liabilities30,215,800
Total Stockholder Equity298,428,000
Total Current Liabilities
Short Long Term Debt 41,803,200
Accounts payable 44,541,600
Other Current Liabilities 2,803,300
Total Current Liabilities  (as reported)121,991,300
Total Current Liabilities  (calculated)89,148,100
+/- 32,843,200
Long-term Liabilities
Long term Debt 21,349,000
Capital Lease Obligations Min Short Term Debt3,324,100
Long-term Liabilities Other 364,700
Long-term Liabilities  (as reported)30,215,800
Long-term Liabilities  (calculated)25,037,800
+/- 5,178,000
Total Stockholder Equity
Retained Earnings 268,014,200
Total Stockholder Equity (as reported)298,428,000
Total Stockholder Equity (calculated)268,014,200
+/- 30,413,800
Other
Capital Stock585,900
Common Stock Shares Outstanding 585,939
Net Debt 29,217,400
Net Invested Capital 361,580,200
Net Working Capital 120,065,000
Property Plant and Equipment Gross 207,843,800



6.2. Balance Sheets Structured

Currency in INR. All numbers in thousands.

 Trend2024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
> Total Assets 
0
0
264,543,700
289,263,500
338,539,900
339,217,200
398,899,900
450,715,100
450,715,100398,899,900339,217,200338,539,900289,263,500264,543,70000
   > Total Current Assets 
92,061,800
121,781,600
153,323,000
164,125,100
198,235,100
181,226,900
215,456,700
242,056,300
242,056,300215,456,700181,226,900198,235,100164,125,100153,323,000121,781,60092,061,800
       Cash And Cash Equivalents 
0
0
18,554,300
27,637,100
53,734,700
41,625,100
43,962,900
33,934,800
33,934,80043,962,90041,625,10053,734,70027,637,10018,554,30000
       Short-term Investments 
0
0
735,000
784,600
2,477,300
3,951,300
21,292,600
29,316,900
29,316,90021,292,6003,951,3002,477,300784,600735,00000
       Net Receivables 
38,454,300
43,121,800
53,374,200
43,151,600
35,032,800
40,122,600
44,663,800
48,167,400
48,167,40044,663,80040,122,60035,032,80043,151,60053,374,20043,121,80038,454,300
       Inventory 
43,305,400
58,584,100
72,456,000
76,998,700
90,265,700
75,538,500
85,112,300
98,082,300
98,082,30085,112,30075,538,50090,265,70076,998,70072,456,00058,584,10043,305,400
       Other Current Assets 
5,167,100
7,472,000
7,944,500
10,548,100
11,500,100
16,156,500
23,204,300
25,364,300
25,364,30023,204,30016,156,50011,500,10010,548,1007,944,5007,472,0005,167,100
   > Long-term Assets 
0
0
110,898,600
125,138,500
140,304,800
157,990,300
183,443,200
208,658,800
208,658,800183,443,200157,990,300140,304,800125,138,500110,898,60000
       Property Plant Equipment 
53,204,100
61,361,000
70,355,900
81,166,300
93,155,100
106,659,900
124,917,800
144,116,900
144,116,900124,917,800106,659,90093,155,10081,166,30070,355,90061,361,00053,204,100
       Goodwill 
0
0
8,325,100
9,159,400
4,289,000
4,754,200
5,960,700
5,951,500
5,951,5005,960,7004,754,2004,289,0009,159,4008,325,10000
       Intangible Assets 
0
0
22,752,100
23,498,400
26,907,000
31,378,700
33,258,500
34,814,600
34,814,60033,258,50031,378,70026,907,00023,498,40022,752,10000
       Long-term Assets Other 
0
0
230,400
2,075,500
-800
100
4,169,300
2,299,600
2,299,6004,169,300100-8002,075,500230,40000
> Total Liabilities 
0
0
125,620,000
121,158,300
119,250,000
93,476,700
130,381,400
152,207,100
152,207,100130,381,40093,476,700119,250,000121,158,300125,620,00000
   > Total Current Liabilities 
66,056,000
86,658,900
120,205,700
113,846,400
106,650,500
81,559,800
114,937,800
121,991,300
121,991,300114,937,80081,559,800106,650,500113,846,400120,205,70086,658,90066,056,000
       Short Long Term Debt 
0
0
67,710,900
59,258,400
50,145,900
25,512,500
42,425,600
41,803,200
41,803,20042,425,60025,512,50050,145,90059,258,40067,710,90000
       Accounts payable 
21,547,000
23,729,000
25,521,800
25,760,600
27,946,800
27,030,500
38,713,100
44,541,600
44,541,60038,713,10027,030,50027,946,80025,760,60025,521,80023,729,00021,547,000
       Other Current Liabilities 
9,213,600
16,255,400
7,949,900
11,749,000
14,741,600
19,530,300
32,767,500
2,803,300
2,803,30032,767,50019,530,30014,741,60011,749,0007,949,90016,255,4009,213,600
   > Long-term Liabilities 
0
0
5,191,000
7,290,800
12,598,500
11,916,900
15,443,600
30,215,800
30,215,80015,443,60011,916,90012,598,5007,290,8005,191,00000
       Capital Lease Obligations Min Short Term Debt
0
0
646,000
3,753,800
3,668,100
4,785,000
4,246,900
3,324,100
3,324,1004,246,9004,785,0003,668,1003,753,800646,00000
       Long-term Liabilities Other 
0
0
113,000
874,800
395,000
297,700
-15,153,200
364,700
364,700-15,153,200297,700395,000874,800113,00000
       Deferred Long Term Liability 
74,100
19,000
37,600
78,200
1,361,000
1,791,600
0
0
001,791,6001,361,00078,20037,60019,00074,100
> Total Stockholder Equity
0
0
138,907,800
168,103,800
219,298,700
245,759,800
268,398,500
298,428,000
298,428,000268,398,500245,759,800219,298,700168,103,800138,907,80000
   Common Stock
585,900
585,900
585,900
585,900
585,900
585,900
585,900
0
0585,900585,900585,900585,900585,900585,900585,900
   Retained Earnings Total Equity00000000
   Accumulated Other Comprehensive Income 00000000
   Capital Surplus 00000000
   Treasury Stock00000000
   Other Stockholders Equity 
298,200
1,793,400
1,852,400
4,926,300
5,034,700
7,673,500
267,812,600
0
0267,812,6007,673,5005,034,7004,926,3001,852,4001,793,400298,200



6.3. Balance Sheets

Currency in INR. All numbers in thousands.




6.4. Cash Flows

Currency in INR. All numbers in thousands.




6.5. Income Statements

Currency in INR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-03-31. Currency in INR. All numbers in thousands.

Gross Profit (+$)
totalRevenue287,045,000
Cost of Revenue-132,362,100
Gross Profit154,682,900154,682,900
 
Operating Income (+$)
Gross Profit154,682,900
Operating Expense-243,137,900
Operating Income43,907,100-88,455,000
 
Operating Expense (+$)
Research Development756,300
Selling General Administrative25,024,100
Selling And Marketing Expenses0
Operating Expense243,137,90025,780,400
 
Net Interest Income (+$)
Interest Income2,857,600
Interest Expense-2,680,900
Other Finance Cost-216,200
Net Interest Income-39,500
 
Pretax Income (+$)
Operating Income43,907,100
Net Interest Income-39,500
Other Non-Operating Income Expenses0
Income Before Tax (EBT)43,799,90043,907,100
EBIT - interestExpense = -2,680,900
31,729,700
34,410,600
Interest Expense2,680,900
Earnings Before Interest and Taxes (EBIT)046,480,800
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax43,799,900
Tax Provision-12,110,200
Net Income From Continuing Ops31,689,70031,689,700
Net Income31,729,700
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net039,500
 

Technical Analysis of Aurobindo
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aurobindo. The general trend of Aurobindo is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aurobindo's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of AUROBINDO PHARMA LTD..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1,422 < 1,530 < 1,582.

The bearish price targets are: 1,203 > 1,181 > 1,109.

Tweet this
AUROBINDO PHARMA LTD. Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of AUROBINDO PHARMA LTD.. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

AUROBINDO PHARMA LTD. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of AUROBINDO PHARMA LTD.. The current macd is -49.54907825.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aurobindo price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aurobindo. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aurobindo price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
AUROBINDO PHARMA LTD. Daily Moving Average Convergence/Divergence (MACD) ChartAUROBINDO PHARMA LTD. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of AUROBINDO PHARMA LTD.. The current adx is 55.69.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Aurobindo shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
AUROBINDO PHARMA LTD. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of AUROBINDO PHARMA LTD.. The current sar is 1,203.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
AUROBINDO PHARMA LTD. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of AUROBINDO PHARMA LTD.. The current rsi is 37.91. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
AUROBINDO PHARMA LTD. Daily Relative Strength Index (RSI) ChartAUROBINDO PHARMA LTD. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of AUROBINDO PHARMA LTD.. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aurobindo price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
AUROBINDO PHARMA LTD. Daily Stochastic Oscillator ChartAUROBINDO PHARMA LTD. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of AUROBINDO PHARMA LTD.. The current cci is -35.94446604.

AUROBINDO PHARMA LTD. Daily Commodity Channel Index (CCI) ChartAUROBINDO PHARMA LTD. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of AUROBINDO PHARMA LTD.. The current cmo is -9.50146042.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
AUROBINDO PHARMA LTD. Daily Chande Momentum Oscillator (CMO) ChartAUROBINDO PHARMA LTD. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of AUROBINDO PHARMA LTD.. The current willr is -62.02732761.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Aurobindo is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
AUROBINDO PHARMA LTD. Daily Williams %R ChartAUROBINDO PHARMA LTD. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of AUROBINDO PHARMA LTD..

AUROBINDO PHARMA LTD. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of AUROBINDO PHARMA LTD.. The current atr is 32.98.

AUROBINDO PHARMA LTD. Daily Average True Range (ATR) ChartAUROBINDO PHARMA LTD. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of AUROBINDO PHARMA LTD.. The current obv is 5,610,056.

AUROBINDO PHARMA LTD. Daily On-Balance Volume (OBV) ChartAUROBINDO PHARMA LTD. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of AUROBINDO PHARMA LTD.. The current mfi is 21.43.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
AUROBINDO PHARMA LTD. Daily Money Flow Index (MFI) ChartAUROBINDO PHARMA LTD. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for AUROBINDO PHARMA LTD..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-15BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-04MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-30BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

AUROBINDO PHARMA LTD. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of AUROBINDO PHARMA LTD. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.914
Ma 20Greater thanMa 501,284.960
Ma 50Greater thanMa 1001,395.216
Ma 100Greater thanMa 2001,430.935
OpenGreater thanClose1,239.000
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aurobindo with someone you think should read this too:
  • Are you bullish or bearish on Aurobindo? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aurobindo? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about AUROBINDO PHARMA LTD.

I send you an email if I find something interesting about AUROBINDO PHARMA LTD..


Comments

How you think about this?

Leave a comment

Stay informed about AUROBINDO PHARMA LTD..

Receive notifications about AUROBINDO PHARMA LTD. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.